Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.74 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.74 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.73 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5313637 | 0.91 | ALDH1A1 (0.61) | GABRA1GABRB2GABRB1GABRA3KDM4E | |
| SCHEMBL30175047 | 0.91 | ALDH1A1 (0.61) | GABRA1GABRB2GABRB1GABRA3KDM4E | |
| SCHEMBL4742551 | 0.90 | GABRA1 (0.63) | GABRA1GABRB2GABRB1GABRA3KDM4E | |
| SCHEMBL7284420 | 0.86 | GABRA1 (0.78) | GABRA1GABRB2GABRB1GABRA3KDM4E | |
| SCHEMBL30417619 | 0.86 | GABRA1 (0.78) | GABRA1GABRB2GABRB1GABRA3KDM4E | |
| SCHEMBL7291769 | 0.85 | GABRA1 (1.00) | GABRA1GABRB2GABRB1GABRA3ALDH1A1 | |
| SCHEMBL1366633 | 0.84 | GABRA1 (0.74) | GABRA1GABRB2GABRB1GABRA3ALDH1A1 | |
| SCHEMBL7381114 | 0.84 | GABRA1 (1.00) | GABRA1GABRB2GABRB1GABRA3ALDH1A1 | |
| SCHEMBL22886423 | 0.84 | GABRA1 (0.74) | GABRA1GABRB2GABRB1GABRA3ALDH1A1 | |
| SCHEMBL1211778 | 0.84 | GABRA1 (0.74) | GABRA1GABRB2GABRB1GABRA3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109651247-A | A kind of green high-efficient synthetic method of carbostyril compound | 云南民族大学 | 2019-04-19 | — | — | CN | disclosed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| EP-1603883-B1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-28 | — | — | EP | disclosed |
| EP-2308848-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | Janssen Pharmaceutica NV (BE) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308848-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | Janssen Pharmaceutica NV (BE) | 2011-04-13 | — | — | EP | disclosed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | disclosed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | disclosed |
| EP-1603883-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-14 | — | — | EP | disclosed |
| CN-1176921-C | Hemihydrochloride salt of 8-cyano-1-cyclopropyl-7- (1S, 6S-2, 8-diazabicyclo [4.3.0] non-8-yl) -6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid | — | 2004-11-24 | — | — | CN | disclosed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | disclosed |
| WO-2004069792-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (US) | 2004-08-19 | — | — | WO | disclosed |
| CN-1328557-A | Hemihydrochloride salt of 8-cyano-1-cyclopropyl-7- (1S, 6S-2, 8-diazabicyclo [4.3.0] non-8-yl) -6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid | BAYER AG (DE) | 2001-12-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | TRPV1, OPRL1, TRPV2 | GABRA1 183/4885GABRB2 501/4885GABRB1 403/4885 |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | TRPV1, OPRL1, TRPV2 | GABRA1 183/4885GABRB2 501/4885GABRB1 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.